| Originalsprog | Engelsk |
|---|---|
| Tidsskrift | Annals of Oncology |
| Vol/bind | 32 |
| Udgave nummer | 1 |
| Sider (fra-til) | 23-33 |
| Antal sider | 11 |
| ISSN | 0923-7534 |
| DOI | |
| Status | Udgivet - 2021 |
Bibliografisk note
Funding Information:BE has reported honoraria from Celgene, Gilead, Novartis, Janssen, Roche, AbbVie, ArQule and has participated at advisory boards for the same companies, she has received research grants from Roche, AbbVie, Janssen, Gilead and BeiGene; TR has reported honoraria from Roche and Janssen and research grants from Roche, Janssen, GlaxoSmithKline, Pharmacyclics and Gilead; EM has reported honoraria from Janssen, Pharmacyclics and Menarini; PG has reported honoraria from AbbVie, Acerta/AstraZeneca, ArQule, BeiGene, Dynamo, Gilead, Janssen, Juno/Celgene, MEI Pharma, Sunesis and research grants from AbbVie, Janssen, Gilead, Novartis and Sunesis; CN has reported honoraria and/or research support from AbbVie, Janssen, Roche, Sunesis, AstraZeneca, Acerta, Novartis and CSL Behring; AK has reported honoraria from Roche/Genentech, Janssen, AbbVie and Acerta and has participated at advisory boards for the same companies, he has received research grants from Roche, Janssen, Celgene, Acerta and AbbVie; MG has reported honoraria from Abbvie, Celgene, Gilead, Janssen, Mundipharma, Novartis and Roche; FC has reported honoraria from Gilead, Sunesis, Janssen, Roche, AstraZeneca and AbbVie and has participated at advisory boards for the same companies, she has received research grants from Sunesis; CB has reported honoraria from Roche, Janssen, Pfizer, Celltrion, AbbVie and research grants from Roche, Janssen and Bayer; PH has reported honoraria for consulting and speaker activities from AbbVie, Celgene and Janssen and has received research grants from Pharmacyclics, Janssen, AbbVie, Gilead and Roche; MH has reported honoraria for consulting and speaker activities from AbbVie, Celgene, Gilead, GlaxoSmithKline, Janssen, Mundipharma and Roche and has received research grants from Mundipharma, Janssen, AbbVie, and Roche; UM has reported honoraria from Roche, Celgene, AbbVie, Mundipharma and Janssen.
Funding Information:
The ESMO Guidelines Committee would like to thank the ESMO Faculty and other experts who provided critical reviews of these ESMO Clinical Practice Guidelines. No external funding has been received for the preparation of these guidelines. Production costs have been covered by ESMO from central funds. BE has reported honoraria from Celgene, Gilead, Novartis, Janssen, Roche, AbbVie, ArQule and has participated at advisory boards for the same companies, she has received research grants from Roche, AbbVie, Janssen, Gilead and BeiGene; TR has reported honoraria from Roche and Janssen and research grants from Roche, Janssen, GlaxoSmithKline, Pharmacyclics and Gilead; EM has reported honoraria from Janssen, Pharmacyclics and Menarini; PG has reported honoraria from AbbVie, Acerta/AstraZeneca, ArQule, BeiGene, Dynamo, Gilead, Janssen, Juno/Celgene, MEI Pharma, Sunesis and research grants from AbbVie, Janssen, Gilead, Novartis and Sunesis; CN has reported honoraria and/or research support from AbbVie, Janssen, Roche, Sunesis, AstraZeneca, Acerta, Novartis and CSL Behring; AK has reported honoraria from Roche/Genentech, Janssen, AbbVie and Acerta and has participated at advisory boards for the same companies, he has received research grants from Roche, Janssen, Celgene, Acerta and AbbVie; MG has reported honoraria from Abbvie, Celgene, Gilead, Janssen, Mundipharma, Novartis and Roche; FC has reported honoraria from Gilead, Sunesis, Janssen, Roche, AstraZeneca and AbbVie and has participated at advisory boards for the same companies, she has received research grants from Sunesis; CB has reported honoraria from Roche, Janssen, Pfizer, Celltrion, AbbVie and research grants from Roche, Janssen and Bayer; PH has reported honoraria for consulting and speaker activities from AbbVie, Celgene and Janssen and has received research grants from Pharmacyclics, Janssen, AbbVie, Gilead and Roche; MH has reported honoraria for consulting and speaker activities from AbbVie, Celgene, Gilead, GlaxoSmithKline, Janssen, Mundipharma and Roche and has received research grants from Mundipharma, Janssen, AbbVie, and Roche; UM has reported honoraria from Roche, Celgene, AbbVie, Mundipharma and Janssen.